Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pharmacokinetically guided dose-escalation (PGDE) strategy].

T Saeki1

  • 1Dept. of Hematology and Oncology, National Cancer Center Hospital East.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvement of treatment outcomes after implementation of comprehensive pharmaceutical care in breast cancer patients receiving everolimus and exemestane.

Die Pharmazie·2018
Same author

Top-down assessment of the Asian carbon budget since the mid 1990s.

Nature communications·2016
Same author

Differential activation of dopaminergic systems in rat brain basal ganglia by morphine and methamphetamine.

Neuroscience·2016
Same author

Search for charged Higgs bosons in e<sup>+</sup>e<sup>-</sup> collisions at [Formula: see text].

The European physical journal. C, Particles and fields·2015
Same author

International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease.

Arthritis & rheumatology (Hoboken, N.J.)·2015
Same author

MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer.

Scientific reports·2015
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Pharmacokinetically guided dose-escalation (PGDE) enables rapid and safe dose increases in early cancer trials. This strategy helps determine the maximum tolerated dose (MTD) for new anti-cancer drugs efficiently.

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Drug Development

Context:

  • Phase I clinical trials are crucial for evaluating new cancer therapies.
  • Dose escalation is a critical component of Phase I trials, balancing safety and efficacy.
  • Preclinical data necessitates rapid and safe dose escalation strategies.

Purpose:

  • To introduce and evaluate a pharmacokinetically guided dose-escalation (PGDE) strategy.
  • To accelerate the dose escalation process in early-phase oncology trials.
  • To efficiently determine the maximum tolerated dose (MTD) for anti-cancer agents.

Summary:

  • The PGDE strategy accelerates dose escalation by targeting 40% of the area under the curve (AUC).
  • This method facilitates a faster and safer approach to identifying the MTD compared to traditional methods.

Related Experiment Videos

  • PGDE is demonstrated as a useful strategy for dose determination in Phase I trials.

    • Impact:

    • PGDE can optimize the efficiency of early-phase cancer drug development.
    • Accelerated MTD determination allows for quicker progression to later trial phases.
    • Improves the safety and speed of introducing novel anti-cancer therapeutics.